SCHEMBL13744607

SCHEMBL13744607

Nc1cc(Cl)cc(Cl)c1C(=O)NCc1cccc(I)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
PLA2G1B P04054 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
GAA P10253 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ATG4B Q9Y4P1 1/20 0.43
ALDH2 P05091 1/20 0.42
HPGD P15428 4/20 0.41
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 1/20 0.41
TP53 P04637 2/20 0.41
MDM2 Q00987 2/20 0.41
LMNA P02545 1/20 0.40
NPC1 O15118 1/20 0.40
HDAC1 Q13547 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4082388 0.88 NPC1 (0.51) MEN1KMT2AHPGDLMNANPC1
SCHEMBL13744508 0.86 MEN1 (0.43) MEN1KMT2ACYP2C19TDP1ALDH2
SCHEMBL4223833 0.85 TP53 (0.54) MEN1KMT2ACYP1A2CYP3A4GAA
SCHEMBL13744513 0.85 KDM4E (0.60) MEN1KMT2APLA2G1BCYP1A2CYP3A4
SCHEMBL4223614 0.85 ALOX5 (0.47) MEN1KMT2APLA2G1BCYP1A2CYP3A4
SCHEMBL4218940 0.85 DPP4 (0.47) MEN1KMT2APLA2G1BCYP1A2CYP3A4
SCHEMBL13744517 0.82 ALDH1A1 (0.62) CYP3A4CYP2D6HPGDALDH1A1KDM4E
SCHEMBL14303918 0.82 DPP4 (0.33) CYP1A2CYP2D6CYP2C19HDAC1ADORA1
SCHEMBL4214266 0.81 CYP2C19 (0.53) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL13744675 0.81 AKR1B1 (0.53) MEN1KMT2ACYP1A2CYP3A4GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203708-A1 NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2009-08-13 US disclosed
US-20090203708-A1 NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203708-A1 NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME HTR5A, HTR3B, HTR1A MEN1 3793/4885KMT2A 4058/4885PLA2G1B 1259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.